Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Angewandte Chemie (International Ed. in English)|June 3, 2025
Beyond Conventional Doping: Sulfur-Induced Electronic and Interfacial Dynamics for Advanced Nitrate ReductionQinghao Zhang, Weilan Ye, Wenda Chen, et al.
Cell Reports. Medicine|September 9, 2025
Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockadeKabir A Khan, Maresa Caunt Mitzner, William Cruz-Munoz, et al.
Blood|July 27, 2013
Rasip1 regulates vertebrate vascular endothelial junction stability through Epac1-Rap1 signalingChristopher W Wilson, Leon H Parker, Christopher J Hall, et al.
Cancer Chemotherapy and Pharmacology|June 16, 2018
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumorsColin D Weekes, Lee S Rosen, Anna Capasso, et al.
EMBO Reports|January 9, 2023
T cell-dependent bispecific antibodies alter organ-specific endothelial cell-T cell interactionPatricia Himmels, Thi Thu Thao Nguyen, Maresa Caunt Mitzner, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2014
Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitorsLan Wang, Mark Stanley, Jason W Boggs, et al.
EMBO Molecular Medicine|August 2, 2018
EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumorsNevenka Dudvarski Stanković, Frank Bicker, Stefanie Keller, et al.
The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Nature Immunology|March 25, 2022
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccinesSiri Tahtinen, Ann-Jay Tong, Patricia Himmels, et al.
Nature Genetics|June 11, 2026
Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy responseAmanda R Moore, Brian Biehs, Noelyn Kljavin, et al.
Pageof 4